Guizhou Sanli PharmaceuticalLtd Future Growth
Future criteria checks 4/6
Guizhou Sanli PharmaceuticalLtd is forecast to grow earnings and revenue by 21.2% and 24.4% per annum respectively. EPS is expected to grow by 21% per annum. Return on equity is forecast to be 19.3% in 3 years.
Key information
21.2%
Earnings growth rate
21.0%
EPS growth rate
| Pharmaceuticals earnings growth | 17.9% |
| Revenue growth rate | 24.4% |
| Future return on equity | 19.3% |
| Analyst coverage | Low |
| Last updated | 20 Jun 2024 |
Recent future growth updates
No updates
Recent updates
Guizhou Sanli Pharmaceutical Co.,Ltd's (SHSE:603439) Intrinsic Value Is Potentially 73% Above Its Share Price
Apr 23
Guizhou Sanli PharmaceuticalLtd (SHSE:603439) Seems To Use Debt Rather Sparingly
Mar 25Guizhou Sanli Pharmaceutical Co.,Ltd's (SHSE:603439) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Mar 06Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 3,476 | 523 | N/A | 502 | 2 |
| 12/31/2025 | 2,959 | 437 | N/A | 614 | 3 |
| 12/31/2024 | 2,388 | 339 | N/A | 25 | 2 |
| 3/31/2024 | 1,708 | 294 | 205 | 284 | N/A |
| 12/31/2023 | 1,635 | 293 | 168 | 277 | N/A |
| 9/30/2023 | 1,461 | 256 | 215 | 334 | N/A |
| 6/30/2023 | 1,402 | 238 | 200 | 309 | N/A |
| 3/31/2023 | 1,392 | 232 | 81 | 236 | N/A |
| 12/31/2022 | 1,201 | 201 | 173 | 293 | N/A |
| 9/30/2022 | 1,035 | 144 | 42 | 147 | N/A |
| 6/30/2022 | 992 | 147 | 54 | 148 | N/A |
| 3/31/2022 | 968 | 153 | 165 | 182 | N/A |
| 12/31/2021 | 939 | 152 | 129 | 155 | N/A |
| 9/30/2021 | 881 | 157 | 125 | 174 | N/A |
| 6/30/2021 | 725 | 117 | 34 | 103 | N/A |
| 3/31/2021 | 612 | 92 | 36 | 101 | N/A |
| 12/31/2020 | 630 | 94 | 12 | 63 | N/A |
| 9/30/2020 | 676 | 88 | 51 | 78 | N/A |
| 6/30/2020 | 818 | 124 | 121 | 125 | N/A |
| 3/31/2020 | 888 | 137 | 85 | 92 | N/A |
| 12/31/2019 | 884 | 133 | 108 | 116 | N/A |
| 6/30/2019 | 771 | 108 | 91 | 97 | N/A |
| 3/31/2019 | 754 | 104 | 111 | 112 | N/A |
| 12/31/2018 | 722 | 110 | 74 | 75 | N/A |
| 6/30/2018 | 700 | 120 | 65 | 67 | N/A |
| 3/31/2018 | 665 | 106 | 44 | 46 | N/A |
| 12/31/2017 | 638 | 88 | N/A | 57 | N/A |
| 9/30/2017 | 597 | 77 | N/A | 43 | N/A |
| 6/30/2017 | 556 | 66 | N/A | 28 | N/A |
| 3/31/2017 | 501 | 68 | N/A | 19 | N/A |
| 12/31/2016 | 515 | 75 | N/A | 35 | N/A |
| 9/30/2016 | 464 | 69 | N/A | 30 | N/A |
| 6/30/2016 | 414 | 63 | N/A | 26 | N/A |
| 3/31/2016 | 386 | 58 | N/A | 29 | N/A |
| 12/31/2015 | 359 | 53 | N/A | 33 | N/A |
| 9/30/2015 | 325 | 46 | N/A | 28 | N/A |
| 6/30/2015 | 291 | 40 | N/A | 23 | N/A |
| 3/31/2015 | 279 | 34 | N/A | 12 | N/A |
| 12/31/2014 | 267 | 29 | N/A | 1 | N/A |
| 12/31/2013 | 159 | 19 | N/A | 30 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 603439's forecast earnings growth (21.2% per year) is above the savings rate (2.9%).
Earnings vs Market: 603439's earnings (21.2% per year) are forecast to grow slower than the CN market (22.3% per year).
High Growth Earnings: 603439's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 603439's revenue (24.4% per year) is forecast to grow faster than the CN market (13.7% per year).
High Growth Revenue: 603439's revenue (24.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 603439's Return on Equity is forecast to be low in 3 years time (19.3%).